<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="347830a8-8833-26b7-e063-6294a90a1f17"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Hyoscyamine Sulfate Extended-Release Tablets, 0.375 mg</content>
      <br/>
      <content styleCode="bold">Rx only
  <br/>
(Packaged by Pharma Packaging Solutions, LLC dba Tjoapack LLC)
 </content>
   </title>
   <effectiveTime value="20250506"/>
   <setId root="01f97804-a6cb-ce6d-e063-6394a90ae220"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="928861723"/>
            <name>Pharma Packaging Solutions, LLC dba Tjopack LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="623168267"/>
                        <name>Sovereign Pharmaceuticals, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="75929-057" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="928861723"/>
                        <name>Pharma Packaging Solutions, LLC dba Tjoapack LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="75929-057" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3478c99f-a06f-a716-e063-6294a90abd1a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250506"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="75929-057" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Hyoscyamine<suffix>ER</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>hyoscyamine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.375"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F2R8V82B84" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYOSCYAMINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PX44XO846X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYOSCYAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="75929-057-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160501"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160501"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText>capsule shape</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">AP;115</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="NM010">
               <id root="01f97b31-d7c6-3533-e063-6294a90a9ed1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Hyoscyamine sulfate extended-release tablets contain 0.375 mg of hyoscyamine sulfate in a formulation designed for oral b.i.d. dosage.</paragraph>
                  <paragraph>Hyoscyamine sulfate is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids. The empirical formula is (C
 
  <sub>17</sub>H
 
  <sub>23</sub>NO
 
  <sub>3</sub>)
 
  <sub>2</sub>•H
 
  <sub>2</sub>SO
 
  <sub>4</sub>•2H
 
  <sub>2</sub>O and the molecular weight is 712.85. Chemically, it is benzeneacetic acid, ɑ-(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.] oct-3-yl ester, [3(S)-endo]-, sulfate (2:1), dihydrate with the following structure:

 </paragraph>
                  <renderMultiMedia ID="id261" referencedObject="MM150"/>
                  <paragraph>Each tablet also contains as inactive ingredients: calcium phosphate dibasic, ethylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose and stearic acid.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
               <component>
                  <observationMedia ID="MM150">
                     <text>Hyoscyamine Sulfate Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="hyoscyamine-er-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="NM020">
               <id root="01f97b31-d7c7-3533-e063-6294a90a9ed1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Hyoscyamine sulfate inhibits specifically the actions of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of the smooth muscle, the cardiac muscle, the sinoatrial node, the atrioventricular node, and the exocrine glands. At therapeutic doses, it is completely devoid of any action on autonomic ganglia. Hyoscyamine sulfate inhibits gastrointestinal propulsive motility and decreases gastric acid secretion. Hyoscyamine sulfate also controls excessive pharyngeal, tracheal, and bronchial secretions.</paragraph>
                  <paragraph>Hyoscyamine sulfate is absorbed totally and completely by oral administration. Once absorbed, hyoscyamine sulfate disappears rapidly from the blood and is distributed throughout the entire body: the half-life of hyoscyamine sulfate is 2 to 3½ hours. Hyoscyamine sulfate is partly hydrolyzed to tropic acid and tropine but the majority of the drug is excreted in the urine unchanged within the first 12 hours. Only traces of this drug are found in breast milk. Hyoscyamine sulfate passes the blood brain barrier and the placental barrier.</paragraph>
                  <paragraph>Hyoscyamine sulfate extended-release tablets releases 0.375 mg hyoscyamine sulfate at a controlled and predictable rate for 12 hours. The mean peak plasma concentration occurred at 4.20 hours. The mean (±SEM) apparent plasma elimination half-life is 7.47 hours (±0.60). Tablets may not completely disintegrate and may be excreted by some patients.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
            </section>
         </component>
         <component>
            <section ID="NM030">
               <id root="01f97b31-d7c8-3533-e063-6294a90a9ed1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Hyoscyamine sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer. They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder andmneurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Hyoscyamine sulfate extended-release tablets are indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a “drying agent” in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
            </section>
         </component>
         <component>
            <section ID="NM040">
               <id root="01f97b31-d7c9-3533-e063-6294a90a9ed1"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis); paralytic ileus, intestinal atony of elderly or debilitated patients; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
            </section>
         </component>
         <component>
            <section ID="NM050">
               <id root="01f97b31-d7ca-3533-e063-6294a90a9ed1"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>In the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating). Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness, or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.</paragraph>
                  <paragraph>Psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate. CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, euphoria, anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect. These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
            </section>
         </component>
         <component>
            <section ID="NM060">
               <id root="01f97b31-d7cb-3533-e063-6294a90a9ed1"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20160411"/>
               <component>
                  <section ID="NM061">
                     <id root="01f97b31-d7cc-3533-e063-6294a90a9ed1"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Use with caution in patients with: autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, hypertension, and renal disease. Investigate any tachycardia before giving any anticholinergic drugs since they may increase the heart rate. Use with caution in patients with hiatal hernia associated with reflux esophagitis.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
               <component>
                  <section ID="NM062">
                     <id root="01f97b31-d7cd-3533-e063-6294a90a9ed1"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information For Patients</title>
                     <text>
                        <paragraph>Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness, or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug.</paragraph>
                        <paragraph>Use of hyoscyamine sulfate may decrease sweating resulting in heat prostration, fever or heat stroke; febrile patients or those who may be exposed to elevated environmental temperatures should use caution. Tablets may not completely disintegrate and may be excreted by some patients.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
               <component>
                  <section ID="NM063">
                     <id root="01f97b31-d7ce-3533-e063-6294a90a9ed1"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.</paragraph>
                        <paragraph>Antacids may interfere with the absorption of hyoscyamine sulfate.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
               <component>
                  <section ID="NM064">
                     <id root="01f97b31-d7cf-3533-e063-6294a90a9ed1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment Of Fertility</title>
                     <text>
                        <paragraph>No long-term studies in animals have been performed to determine the carcinogenic, mutagenic or impairment of fertility potential of hyoscyamine sulfate; however, 40 years of marketing experience with hyoscyamine sulfate shows no demonstrable evidence of a problem.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
               <component>
                  <section ID="NM065">
                     <id root="01f97b31-d7d0-3533-e063-6294a90a9ed1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy – Pregnancy Category C</title>
                     <text>
                        <paragraph>Animal reproduction studies have not been conducted with hyoscyamine sulfate. It is also not known whether hyoscyamine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hyoscyamine sulfate should be given to a pregnant woman only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
               <component>
                  <section ID="NM066">
                     <id root="01f97b31-d7d1-3533-e063-6294a90a9ed1"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Hyoscyamine sulfate is excreted in human milk. Caution should be exercised when hyoscyamine sulfate is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
               <component>
                  <section ID="NM067">
                     <id root="01f97b31-d7d2-3533-e063-6294a90a9ed1"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Reported clinical experience has not identified differences in safety between patients aged 65 and over and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Wallace Pharmaceuticals at 1-800-619-6344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NM070">
               <id root="01f97b31-d7d3-3533-e063-6294a90a9ed1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>All of the following adverse reactions have been reported with hyoscyamine sulfate. Adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; constipation; bloated feeling; abdominal pain; diarrhea; allergic reactions or drug idiosyncrasies; urticaria and other dermal manifestations; ataxia; speech disturbance; some degree of mental confusion and/or excitement (especially in elderly persons); short-term memory loss; hallucinations; and decreased sweating.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
            </section>
         </component>
         <component>
            <section ID="NM080">
               <id root="01f97b31-d7d4-3533-e063-6294a90a9ed1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation.</paragraph>
                  <paragraph>Measures to be taken are immediate lavage of the stomach and injection of physostigmine 0.5 to 2 mg intravenously and repeated as necessary up to a total of 5 mg. Fever may be treated symptomatically (tepid water sponge baths, hypothermic blanket). Excitement to a degree which demands attention may be managed with sodium thiopental 2% solution given slowly intravenously or chloral hydrate (100-200 mL of a 2% solution) by rectal infusion. In the event of progression of the curare-like effect to paralysis of the respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.</paragraph>
                  <paragraph>In rats, the LD
 
  <sub>50</sub>for hyoscyamine is 375 mg/kg. Hyoscyamine sulfate is dialyzable.

 </paragraph>
               </text>
               <effectiveTime value="20160411"/>
            </section>
         </component>
         <component>
            <section ID="NM090">
               <id root="01f97b31-d7d5-3533-e063-6294a90a9ed1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Dosage may be adjusted according to the conditions and severity of symptoms.</paragraph>
               </text>
               <effectiveTime value="20160411"/>
               <component>
                  <section ID="NM091">
                     <id root="01f97b31-d7d6-3533-e063-6294a90a9ed1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults And Pediatric Patients 12 Years Of Age And Older</title>
                     <text>
                        <paragraph>1 to 2 tablets every 12 hours. Do not crush or chew tablets. Do not exceed 4 tablets in 24 hours.</paragraph>
                     </text>
                     <effectiveTime value="20160411"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="NM100">
               <id root="01fd3c11-9f95-9bc5-e063-6394a90a999a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Hyoscyamine Sulfate Extended-Release Tablets, 0.375 mg are white, capsule-shaped tablets. They are coded “AP” on one side and “115” on the other.</paragraph>
                  <paragraph>Bottles of 100 tablets          NDC 75929-057-10</paragraph>
                  <paragraph>Store at controlled room temperature 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Please refer to current USP.</paragraph>
                  <paragraph>Dispense in tight, light-resistant containers as defined in USP/NF with a child-resistant closure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">KEEP OUT OF REACH OF CHILDREN</content>
                  </paragraph>
                  <paragraph>Also available as:</paragraph>
                  <table width="100%">
                     <colgroup>
                        <col width="40%"/>
                        <col width="20%"/>
                        <col width="20%"/>
                        <col width="20%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule " valign="top"/>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Dosage</content>
                                 <br/>
                                 <content styleCode="bold">Strength</content>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Package</content>
                                 <br/>
                                 <content styleCode="bold">Size</content>
                              </paragraph>
                           </td>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top">
                              <paragraph>Hyoscyamine Sulfate
      <br/>
			Tablets, USP
     </paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>0.125 mg</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>100</paragraph>
                           </td>
                           <td valign="top">
                              <paragraph>75929-055-10</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>Hyoscyamine Sulfate
      <br/>
			Sublingual Tablets
     </paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>0.125 mg</paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>100</paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>75929-056-10</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Distributed by:
  <br/>
Wallace Pharmaceuticals Inc.
  <br/>
Somerset, New Jersey 08873-4120
  <br/>
©2018 Mylan Pharmaceuticals Inc
 </paragraph>
                  <paragraph>WALLACE and 
  <renderMultiMedia referencedObject="MM160"/>are trademarks of Wallace Pharmaceuticals Inc., a Mylan company
 </paragraph>
                  <paragraph>IN-1151-03                 Rev. 3/2018</paragraph>
                  <paragraph>Printed in USA</paragraph>
                  <paragraph>70011278</paragraph>
               </text>
               <effectiveTime value="20160411"/>
               <component>
                  <observationMedia ID="MM160">
                     <text>Wallace Pharmaceuticals Inc. Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="hyoscyamine-er-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="PDP01">
               <id root="01fd2476-5ddf-a087-e063-6394a90afdd0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Hyoscyamine ER .375 mg</title>
               <text>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">NDC 75929-057-10</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Hyoscyamine Sulfate
   <br/>
Extended-Release
   <br/>
Tablets
   <br/>
0.375 mg
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Each tablet contains 0.375 mg hyoscyamine sulfate, USP.</paragraph>
                  <paragraph>
                     <content styleCode="bold">USUAL DOSAGE:</content>Adults and pediatric patients 12 years
  <br/>
of age and older: 1 to 2 tablets every 12 hours.
 </paragraph>
                  <paragraph>See package insert for full prescribing information.</paragraph>
                  <paragraph>Dispense in tight, light-resistant containers as
  <br/>
defined in USP/NF with child-resistant closure.
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">KEEP OUT OF REACH OF CHILDREN.</content>
                  </paragraph>
                  <paragraph>Store at controlled room temperature 20º-25ºC (68º-77ºF);
  <br/>
excursions permitted to 15º-30ºC (59º-86ºF).
  <br/>
Please refer to current USP.
 </paragraph>
                  <paragraph>Distributed by: Wallace Pharmaceuticals Inc.
  <br/>
Somerset, NJ 08873-4120, USA
 </paragraph>
                  <paragraph>For medical inquiries call 1-800-619-6344</paragraph>
                  <paragraph>©2018 Mylan Pharmaceuticals Inc.</paragraph>
                  <paragraph>LB-115103-03 REV 3/2018</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_01fd424d-707c-aeca-e063-6394a90a4925"/>
                  </paragraph>
               </text>
               <effectiveTime value="20160411"/>
               <component>
                  <observationMedia ID="img_01fd424d-707c-aeca-e063-6394a90a4925">
                     <text>Bottle1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Bottle1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>